Sophie E. Berends, Anne S. Strik, Jeroen M. Jansen, Nanne K.H. de Boer, Pleun S. van Egmond, Johannan F. Brandse, Ron A. A. Mathôt, Geert R. D’Haens, Mark Löwenberg,
Background: Golimumab (GLM) is approved for the treatment of moderate to severe ulcerative colitis (UC). Higher serum concentrations of anti-tumor necrosis factor (TNF) agents are associated with improved clinical and endoscopic outcomes. Correlations between GLM serum concentrations and clinical and endoscopic outcomes were investigated during induction and maintenance treatment. In addition, a population pharmacokinetic model was developed to identify factors associated with the pharmacokinetics ...
Tópico(s): Diagnosis and treatment of tuberculosis
2019 - Taylor & Francis | Scandinavian Journal of Gastroenterology